Podcasts about Dubey

Ask Dubey episode 6 is live! Today Devan Dubnyk answers your questions from the past week and breaks down the current state of the Conference Finals and the Edmonton Oilers taking a stranglehold on the series.Then Devan jumped into your questions! Dubey gave his thoughts on how goalies can struggle vs certain teams, who is Dubey's favorite Oiler, who had the craziest superstitions from his days in Edmonton, What are the most saves Dubey's ever made in a game and then Dubey gave his thoughts on Darnell Nurse's slash on Roope HintzDon't forget to comment whatever questions you want Dubey to answer next week or use #AskDubey on social media!

Ask Dubey episode 5 is live! Today Devan Dubnyk answers your questions from the past week and breaks down the Edmonton Oilers taking on the Dallas Stars in the Western Conference Finals for the second time in two years. Then Devan jumped into your questions! Dubey gave his thoughts on how equipment impacts a NHL goaltender, who is Dubey's favorite goalie in the NHL, how hard is it to play in Edmonton, how hard is it for a goalie after letting in a weak goal and what the Edmonton Oilers have to take a series lead over the Stars?Don't forget to comment whatever questions you want Dubey to answer next week or use #AskDubey on social media!

Ask Dubey episode 4 is live! Today Devan Dubnyk answers your questions from the past week and breaks down the Edmonton Oilers re-taking charge of their round 2 matchup vs the Golden Knights after Then Devan jumped into your questions! Dubey gave his thoughts on the impact a goalie coach has on a starter and a backup, do stiffer pads create better rebounds, how a goaltenders vision dictates which side they feel more comfortable, and what the Edmonton Oilers have to do to close out the Golden Knights?Don't forget to comment whatever questions you want Dubey to answer next week or use #AskDubey on social media!

Supreme Court Waqf Act की सुनवाई से हटा पीछे | Opposition Shocked | Nishikant Dubey Case Dismissed

Listen: Lauren Class Schneider talks to Nicola Murphy Dubey, the director of “Irishtown” at the Irish Repertory Theatre. “Class Notes” actively covers New York's current theater season on, off, and off-off Broadway. Angela Reed, Kevin Oliver Lynch, Kate Burton, Saoirse-Monica Jackson, and Brenda Meaney in Irish Rep’s 2025 production of read more The post Class Notes: Nicola Murphy Dubey “Irishtown” appeared first on BroadwayRadio.

FlamesNation Barn Burner with Boomer, Pinder & WarrenerSHOW TIMESTAMPShttps://www.youtube.com/live/NblK6gL53aQ Intro Banter (1:00)- EDM/LA (4:00)- Challenge So Dumb (5:00)- Get The Puck Out (11:00- OT Winner (14:00)-------------------------------------------------- Dubby Joins (21:00)- LA/EDM (23:00)- Skinner/Pickard (25:00)- Hellebuyck (31:30)- Binnington (34:30)- Landeskog (36:30)- Life Update (38:00)-------------------------------------------------- Dubey (43:00)- Jets vs Blues (46:30)- Capitals (50:00)- Pinder Report (55:00)- Bet365 (01:28:00)FLAMESNATION MERCHhttps://nationgear.ca/collections/flamesnationBARN BURNER CLIPShttps://www.youtube.com/playlist?list=PLj_bcGtvvo-cW2DHEDZ6dEO5ePDmlhZc9SHOUTOUT TO OUR SPONSORS!!

From the Late Arun Jaitley's ‘tyranny of the unelected' jibe to Nishikant Dubey holding CJI Khanna responsible for ‘civil wars'- how and why the Supreme Court has been in the BJP's crosshairs, ThePrint Political Editor DK Singh explains in this episode of #PoliticallyCorrect----more----Read this week's Politically Correct here: https://theprint.in/opinion/politically-correct/nishikant-dubey-jp-nadda-attack-cji-sanjiv-khanna/2597624/

Hidden Story Behind JP Nadda vs Nishikant Dubey | SC Collegium | Modi Planning Big | Anupam K Singh

Supreme Court vs Govt में फसे JP Nadda | Dhankhad & Nishi Kant Dubey on FIRE

How has the legal community reacted to BJP MP Nishikant Dubey's remarks on SC & CJI?  ----more---- https://theprint.in/judiciary/legal-community-says-nishikants-remarks-border-on-contempt-backs-scs-approach-to-waqf-law-matter/2596260/

First, The Indian Express Deeptiman Tiwary discusses Mehul Choksi, a key accused in the Punjab National Bank loan fraud, was arrested in Belgium.Second, we talk to The Indian Express' Vidheesha Kuntamalla about the frequent US visa revocations of the Indian students and its implications. (10:59)Lastly, we speak about why BJP MP Nishikant Dubey is again at the center of a controversy. (18:55)Hosted by Ichha SharmaProduced and written by Shashank Bhargava, Niharika Nanda and Ichha SharmaEdited and mixed by Suresh Pawar

More Trouble for Supreme Court after Nishikant Dubey | Ex-HC Judge Complains to President

In this warm and reflective episode of The Mohua Show, Dr. Saroj Dubey—gastroenterologist and author of Rx for Resilience—shares the deeply personal journey that led him to write his book. Born from heartbreak and emotional upheaval, his story is one of growth, healing, and the quiet strength that comes from living in the present moment. Dr. Dubey speaks about acceptance as an active, empowering choice, and how saying “yes” to life even in its messiest moments can transform our inner world.He talks about fear, resilience, and the fleeting nature of thoughts. He also offers gentle wisdom on how mindfulness can be part of even the most demanding careers, and how spiritual teachings, gratitude, and emotional honesty can ground us when life feels overwhelming. This episode is an invitation to slow down, tune in, and embrace every part of your journey with openness, courage, and compassion.Chapters00:00 Highlights01:28 Introduction to Dr. Saroj Dubey and His Journey05:22 Living in the Present Moment08:15 Acceptance and Surrender in Life's Challenges13:07 Saying Yes to Life16:03 Confronting Fear and Embracing Vulnerability18:40 Understanding Transient Thoughts vs. True Nature21:46 Mindfulness in High-Pressure Careers25:40 Influences of Spiritual Thought Leaders33:06 Key Takeaways from 'Rx for Resilience'Connect with UsMohua Chinappa: https://www.linkedin.com/in/mohua-chinappa/The Mohua Show: https://www.themohuashow.com/Connect with the GuestFollow UsInstagram: https://www.instagram.com/themohuashow/Instagram:https://www.instagram.com/litlounge_pod/ YouTube: https://www.youtube.com/@TheMohuaShowLinkedIn: https://www.linkedin.com/company/themohuashow/Facebook: https://www.facebook.com/themohuashowFor any other queries EMAILhello@themohuashow.comDisclaimerThe views expressed by our guests are their own. We do not endorse and are not responsible for any views expressed by our guests on our podcast and its associated platforms.#TheMohuaShow #MohuaChinappa #Podcast #MentalHealth #Doctor #WellBeing #Medicine #Mindfulness #Meditation #Healthcare Thanks for Listening!

This episode is brought to you by HalloCasa, the SEO-ranked digital business card for real estate agents. Looking to find the right agent, no matter where you are?Visit https://home.hallocasa.com/ to discover and connect with top real estate agents globally.Explore and get started today: https://hallocasa.com/brokersIn Episode 154 of HalloCasa, I speak with Nipun, the founder of Happinest.ai, a groundbreaking proptech startup redefining property management. From seamless tenant communication and smart analytics to maximizing rental income and unlocking operational efficiencies, Nipun shares the journey of building Happinest.ai, the tech behind it, and the startup's go-to-market strategy. Learn how property owners and managers can leverage this AI-powered platform to outperform neighborhood benchmarks and scale their operations.00:00:48 Introduction00:02:00 About the Use Cases covered by happiness.ai00:06:50 Lead Qualification Process in Detail00:10:00 Communication between tenants and property managers via happinest.ai and Analytics Features00:10:00 Additional Use Cases from a property management´s point of view00:17:00 Happinest.ai as an orchestra00:24:00 Outperforming the local neighborhood market price through efficiencies with happinest.ai 00:29:40 Using Happinest.ai as an individual property owner and creating strong efficiencies00:35:00 The technology behind happinest.ai00:36:00 Nipun´s previous journey and his motivation to start happinest.ai00:41:20 Happinest.ai Pricing Model00:44:11 Next steps and raising money with Happinest.ai00:47:27 Conclusion and Final ThoughtsFeel free to reach out to Nipun via: https://www.linkedin.com/in/nipundubey/

For the first time in history, the National Indigenous Cricket Championship finals included live commentary in Hindi and Punjabi. Hindi commentator Sanjiv Dubey shared his reflections on the experience, highlighting the unifying power of sport. He spoke about cricket's role in helping Indigenous communities reconnect with the game, drawing on the legacy of Australia's first all-Indigenous cricket tour to England. Dubey believes that bringing multicultural commentary to the field not only makes the sport more accessible but also deepens cultural connections through a shared passion for cricket.

Abhijit Dubey is the CEO of NTT Data, Inc., a $30 billion business and one of the largest IT services providers in the world. Abhijit joins Adam to share his journey and his best lessons and advice. Abhijit and Adam discuss a wide range of topics: leadership, personal and professional development and success, communication, hiring, ethics, trust, innovation, and much more.

It's the story of Chitra and Sudip, two people who meet in Banaras every year on October 10th. They are not friends, not lovers, not married, but they are close in a special way that evades definition.

NTT DATA's CEO on staying true to his values as he leads the company into the future This week Tammy is joined by NTT DATA's Global CEO Abhijit Dubey. Abhijit has worked across the globe and across industries and is now leading NTT DATA into a new phase of growth. Abhijit talks about the importance of remaining grounded as a leader and shares tips on how to overcome imposter syndrome - yes, CEOs can experience imposter syndrome too! He also shares his vision of where the industry is going with agentic AI and how we might onboard AI agents in the future. Links: Abhijit DubeyAbhijit Dubey - World Economic Forum See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

October Junction is a Hindi novel by Divya Prakash Dubey. Its the story of Chitra and Sudip, two people who meet in Banaras every year on October 10th. They are not friends, not lovers, not married, but they are close in a special way that evades definition.

Vinay Dubey is the Co-founder & CMO at wintwealth feedback : ryan@soulsearching.inEPISODE LINKS:Vinay's Linkedin :   / vinay-dubey  PODCAST INFO:Podcast website: https://anchor.fm/ryandsouzaApple Podcasts: https://apple.co/3NQhg6SSpotify: https://spoti.fi/3qJ3tWJAmazon Music: https://amzn.to/3P66j2BGoogle Podcasts: https://bit.ly/3am7rQcGaana: https://bit.ly/3ANS4v1RSS: https://anchor.fm/s/609210d4/podcast/rss

In this insightful episode of The Brand Called You, hosts Sandeep Tyagi converse with the highly accomplished Anshu Dubey, Founder and President of the Brahm Varchas Education Society. Anshu shares her journey from a 20-year career in IT and Fintech to starting an educational society focused on Vedic knowledge. Here are the key takeaways from their conversation, segmented by time stamps for easy reference.

In this insightful episode of The Brand Called You, hosts Sandeep Tyagi converse with the highly accomplished Anshu Dubey, Founder and President of the Brahm Varchas Education Society. Anshu shares her journey from a 20-year career in IT and Fintech to starting an educational society focused on Vedic knowledge. Here are the key takeaways from their conversation, segmented by time stamps for easy reference.

Today we're doing a throwback episode to one of our favorites from the early days of Stories Podcast. Magic pumpkins keep growing in Lakshmi's yard, and she and her brother Dubey can't believe it! In this traditional Indian folktale, we find out what happens when you help someone in need out the goodness of your heart and what happens when you help someone in the hopes of getting a reward. Check out Stories RPG our new show where we play games like Starsworn with all your Max Goodname friends, and Gigacity Guardians featuring the brilliant firefly! https://link.chtbl.com/gigacity Draw us a picture of what you think any of the characters in this story look like, and then tag us in it on instagram @storiespodcast! We'd love to see your artwork and share it on our feed!! If you would like to support Stories Podcast, you can subscribe and give us a five star review on iTunes, check out our merch at storiespodcast.com/shop, follow us on Instagram @storiespodcast, or just tell your friends about us! Check out our new YouTube channel at youtube.com/storiespodcast. If you've ever wanted to read along with our stories, now you can! These read-along versions of our stories are great for early readers trying to improve their skills or even adults learning English for the first time. Check it out.

In this insightful episode of The Brand Called You, hosts Sandeep Tyagi converse with the highly accomplished Anshu Dubey, Founder and President of the Brahm Varchas Education Society. Anshu shares her journey from a 20-year career in IT and Fintech to starting an educational society focused on Vedic knowledge. Here are the key takeaways from their conversation, segmented by time stamps for easy reference.

Rahul Gandhi to Be Arrested? | Nishikant Dubey says Rahul Gunda | Ambedkar | Yogi | Anupam Mishra

इस हफ़्ते पुलियाबाज़ी की मुलाकात हो रही है स्टोरीबाज़ी के साथ। आज हमारे ख़ास मेहमान हैं मशहूर हिंदी लेखक और कहानीकार दिव्य प्रकाश दुबे जिन्होंने कई बेस्टसेलिंग नवलकथाएँ लिखी हैं, स्टोरीटेलिंग के शो भी करते हैं, और फिल्मों में डायलॉग भी लिखे हैं। हिंदी साहित्य जगत में अपनी जगह बनाने के इस सफर को वो आज इस सहज बातचीत में शेयर करते हैं। दिव्य प्रकाश नये ज़माने में उभरती हुई नयी हिंदी के लेखक हैं। नये पुराने किस्सों और यादों से भरी ये पुलियाबाज़ी आप को ज़रूर पसंद आएगी। सुनियेगा ज़रूर।We discuss:* The art of storytelling* Adapting storytelling for different mediums* Nayi Hindi* The challenge with using Hindi for technical topics* The literary ecosystem in Hindi* Is algorithm the new gate keeper?Reading List:https://divyaprakash.in/अब पुलियाबाज़ी में आप भी शामिल हो सकते हैं। इस तरह। Send your Hindi submissions to Puliyabaazi. For details see the link here.Related Puliyabaazi:भारत, एक भाषा संगम। How have Indian languages evolved? ft. Karthik Venkateshहिंदी-उर्दू : इतिहास और राजनीतिकरण. Hindi Urdu Unity ft. Abhishek AvtansPuliyabaazi Playlist on Indian LanguagesIf you have any questions for the guest or feedback for us, please comment here or write to us at puliyabaazi@gmail.com. Please note that Puliyabaazi is now available on Youtube with video. If you like our work, please subscribe and share this Puliyabaazi with your friends, family and colleagues.Website: https://puliyabaazi.inGuest: @divyapdubeyHosts: @saurabhchandra @pranaykotas @thescribblebeeTwitter: @puliyabaaziInstagram: https://www.instagram.com/puliyabaazi/Subscribe & listen to the podcast on iTunes, Google Podcasts, Castbox, AudioBoom, YouTube, Spotify or any other podcast app. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.puliyabaazi.in

I'm so proud to be in North Texas, and we have so many amazing communities. I like to spotlight communities when I can, and so I ran into the mayor of Richardson, Texas, about three weeks ago. I invited him on my television show to talk about all the wonderful things they're doing. Mayor Bob Dubey is in the studio.

Between Triumph and Turmoil: The Corporate Journey of a True BelieverIn this episode of the xMonks Drive podcast, Rajeev Dubey opens up about the extraordinary highs and devastating lows of his corporate journey. From devoting his career to Tata for nearly three decades, to his unexpected resignation as Managing Director of Rallis India, he shares how life threw him a curveball at the pinnacle of his career, thrusting him into uncertainty.But there's much more to Rajeev's story than the corporate ladder. Guided by principles of Satya (Truth), Prem (Love), and Seva (Service), he reflects on the forces that held him together during trying times—and what kept him grounded in the corporate world. From the brink of giving it all up, Rajeev reemerged, inspired by an unforgettable mentor: Anand Mahindra. Described as a rare blend of “head, heart, and soul,” Mahindra became a north star in Rajeev's path, embodying authenticity and trust in every aspect of leadership.Join us for this inspiring conversation as Rajeev reveals his journey of transformation: learning self-acceptance, facing the feeling of inadequacy, and ultimately embracing life after retirement. This episode is a deep dive into what it means to pursue success while staying true to oneself, featuring reflections that will resonate with anyone navigating their own career, purpose, or journey of self-discovery.Follow us on our Instagram: https://www.instagram.com/xmonks.ecosystem/Follow me On YouTube:https://www.youtube.com/channel/UCHsytOG-7i57hrSwB7fNkcwFollow me On LinkedIn:https://www.linkedin.com/in/gauravaroragrv/

In this conversation, Abhijit Dubey, CEO of NTT DATA, discusses the company's global consolidation strategy, uniting its capabilities outside Japan to create a single, full-stack IT services provider. He highlights how this consolidation enhances innovation, sustainability, and client value while addressing the challenges of balancing cost optimization with cutting-edge transformation, the impact of generative AI, and the evolving talent landscape in the industry. You will learn: Global Consolidation: NTT DATA unified global operations to strengthen innovation and client services. Innovation and Sustainability: The company invests 30% of its profits in sustainable, energy-efficient technologies. Generative AI Focus: Significant investments in generative AI, including developing tsuzumi, a lightweight AI model. Skills Arbitrage: A shift toward specialized skills as the key differentiator in IT services. Talent Challenges: Addressing the industry's need for continuous upskilling and talent retention. Also, read the associated Market Vision Paper titled, “NTT DATA: Responsibly reinventing to lead an era of AI-driven transformation” here: https://www.hfsresearch.com/research/ntt-data-responsibly-reinventing-ai-driven/

Pragya Dubey, Vice President of Global Services at Agility PR Solutions is my guest in this episode of the Women in Customer Success podcast.She talks about her career in public relations and customer success. With nearly two decades of experience, she shares insights on how the PR landscape has evolved, especially in the age of social media and the challenges that come with it.She is a leader in customer success, focused on building strong partnerships that help both the business and the clients succeed. She makes sure that people, processes, and business goals all work together smoothly. By building great relationships with clients, leading a motivated team, and focusing on long-term growth, she's built a track record of success. Her approach ensures that both the company and its clients see real and lasting benefits.In this episode, we also talk about:Evolution of public relations (PR)Challenges in modern PRAdvice for PR professionalsThe role of a VP in Global ServicesBuilding relationships with clientsPrinciples of customer successHow to do PR for yourselfHit play and learn from Pragya's experience. Whether you're in PR, customer success, or just looking for inspiration, this episode has something for you. Don't miss it!Follow Pragya!__________________________________________________About Women in Customer Success Podcast: Women in Customer Success Podcast is the first women-only podcast for Customer Success professionals, where remarkable ladies of Customer Success connect, inspire and champion each other. Follow:Women in Customer Success Website - womenincs.co/podcast LinkedIn - linkedin.com/company/womenincs Instagram: https://www.instagram.com/womenincs.co/ Host Marija Skobe-Pilley Website - https://www.marijaskobepilley.com/ LinkedIn - https://www.linkedin.com/in/mspilley/ Get a FREE '9 Habits of Successful CSMs' guide https://www.marijaskobepilley.com/9-habits-freebie NEW - Women in Customer Success Courses: Thriving as a First-Time People Leader - https://womenincs.co/thriving-as-a-first-time-people-leader The Revenue CSM - https://www.marijaskobepilley.com/the-revenue-csm

The climate crisis demands urgent action, yet many people struggle to make meaningful changes. This week, we're joined by Dr. Rachit Dubey to hear about the the psychology behind climate inaction. Dr. Dubey shares insights into why humans are wired to seek rewards, leading to consumerism—a core driver of environmental issues. He breaks down how understanding these psychological patterns can help shape more effective climate policies. We learn the best ways to communicate climate change information. Beth and Ava reflect on how their own experiences have influenced their environmental concerns and actions.

The climate crisis demands urgent action, yet many people struggle to make meaningful changes. This week, we're joined by Dr. Rachit Dubey to hear about the the psychology behind climate inaction. Dr. Dubey shares insights into why humans are wired to seek rewards, leading to consumerism—a core driver of environmental issues. He breaks down how understanding these psychological patterns can help shape more effective climate policies. We learn the best ways to communicate climate change information. Beth and Ava reflect on how their own experiences have influenced their environmental concerns and actions.

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.Show notesSpeaker 3: (00:32) Would you provide a little background on yourself, Dr. Mills? Speaker 3: (01:19) Dr. Dubey? Speaker 3: (02:07) Can you give a brief overview of our demyelinating test and recommended use? Speaker 3: (03:52) Can you discuss how this new test will assist in a patient's journey? Speaker 3: (05:46) Can you tell us some of the unique features of this test? Speaker 3: (08:09) Dr. Dubey, as a neurologist, how does this test set us apart in the market? Speaker 3: (11:05) Could you summarize the benefits of having both a demyelinating panel and an axonal panel? Speaker 3: (11:40) Why should a patient have an axonal or demyelinating test versus a sensory and motor test for peripheral neuropathy?

He's a bestselling writer who's brought Hindi literature into a modern age -- and he also writes films and tells stories. Divya Prakash Dubey joins Amit Varma in episode 399 of The Seen and the Unseen to discuss his life, his language, his society and his art. (FOR FULL LINKED SHOW NOTES, GO TO SEENUNSEEN.IN.) Also check out:1. Divya Prakash Dubey on Instagram, Twitter, LinkedIn, Facebook, IMDb, Amazon and his own website. 2. Musafir Cafe -- Divya Prakash Dubey. 3. October Junction -- Divya Prakash Dubey. 4. Ibnebatuti -- Divya Prakash Dubey. 5. Aako Baako -- Divya Prakash Dubey. 6. Sharten Laagoo -- Divya Prakash Dubey. 7. Masala Chay -- Divya Prakash Dubey. 8. The first episodes of Hum Log, Buniyaad and Byomkesh Bakshi.9. Maya Memsaab -- Ketan Mehta. 10. Raja Hindustani -- Dharmesh Darshan. 11. Deep Work and Slow Productivity -- Cal Newport. 12. Memories, Dreams, Reflections -- Carl Gustav Jung. 13. Private Truths, Public Lies — Timur Kuran. 14. How Not To Get Trolled -- Amit Varma. 15. Kya Bhulu Kya Yaad Karu -- Harivansh Rai Bachchan. 16. Mujhe Chand Chahiye -- Surendra Verma. 17. Shekhar: Ek Jeevani (Hindi) (English) — Agyeya. 18. Self-Portrait — AK Ramanujan. 19. Young India — Episode 83 of The Seen and the Unseen (w Snigdha Poonam). 20. Dreamers: How Young Indians Are Changing Their World — Snigdha Poonam. 21. Husain Ki Kahani, Apni Zubani -- MF Husain. 22. Mrityunjaya -- Shivaji Sawant. 23. Yugandhar -- Shivaji Sawant. 24. जिन मुश्किलों में मुस्कुराना हो मना -- Gopaldas Niraj. 25. Rahi Masoom Raza on Amazon, Wikipedia, Hindwi, Rekhta and IMDb. 26. Kissi Se Na Kehna -- Hrishikesh Mukherjee. 27. Scene: 75 (Hindi) (English) -- Rahi Masoom Raza. 28. Cinema Aur Sanskriti -- Rahi Masoom Raza. 29. Aadha Gaon -- Rahi Masoom Raza. 30. Manohar Shyam Joshi on Amazon, Wikipedia, Hindwi and IMDb. 31. Kathasaritsagara -- Somadeva. 32. Bimal Mitra on Wikipedia, Amazon and IMDb. 33. Chitralekha --  Bhagwaticharan Verma. 34. Nayi Kahani Andolan. 35. Hindi Nationalism -- Alok Rai. 36. The Life and Times of Ira Pande — Episode 369 of The Seen and the Unseen. 37. The Art of Podcasting -- Episode 49 of Everything is Everything. 38. Imaginary Number — Vijay Seshadri. 38. A Piece of String -- Guy de Maupassant. 39. Divya Prakash Dubey's tweet about his influence for dialogue writing. 40. Ponniyin Selvan -- Mani Ratnam. 41. Humankind -- . 42. Bela Sheshe. 43. Anand -- Hrishikesh Mukherjee. 44. 96 -- S Prem Kumar. 45. Notting Hill -- xxx. 46. Ten Years with Guru Dutt -- Abrar Alvi in conversation with Sathya Saran. 47. Tamsoma Jyotirgamay and Peevat Ram Ras Lagi Khumari -- Rajnish aka Osho. 48. Urdu Ki Aakhiree Kitab -- Ibne Insha. 49. कल चौदहवीं की रात थी -- Ibne Insha. 50. Humesha Der Kar Deta Hoon Main — Muneer Niazi. 51. Kunwar Narayan, Vinod Kumar Shukla and Kedarnath Singh. 52. Deewar Mein Ek Khidki Rahti Thi -- Vinod Kumar Shukla. 53. Complete Short Stories -- Guy de Maupassant. 54. Pyramid Ka Sapna -- Jack Harte. This episode is sponsored by The 6% Club, which will get you from idea to launch in 45 days! Amit Varma and Ajay Shah have launched a new video podcast. Check out Everything is Everything on YouTube. Amit's newsletter is active again. Subscribe right away to The India Uncut Newsletter! It's free! Check out Amit's online course, The Art of Clear Writing. Episode art: ‘Naye Waale Writer' by Simahina.

In this compelling episode of the Payments Podium Podcast, the Payments Professor dives into the innovative world of offline payments with Anurag Dubey from Lipis Advisors. Explore the crucial role of offline payments in extending financial inclusion, enhancing payment system resilience, and ensuring continuity during internet outages or in remote locations. Anurag breaks down the technology behind offline payments, including the security protocols and hardware involved, and discusses how countries like India are already successfully implementing these solutions for low-value transactions. This episode is a must-listen for anyone interested in the next frontier of instant payments and how it will reshape global financial systems.

Many autoimmune neuromuscular disorders are reversible with prompt diagnosis and early treatment. Understanding the potential utility and limitations of antibody testing in each clinical setting is critical for practicing neurologists. In this episode, Teshamae Monteith, MD, FAAN speaks with Divyanshu Dubey, MD, FAAN, author of the article “Autoimmune Neuromuscular Disorders Associated With Neural Antibodies,” in the Continuum® August 2024 Autoimmune Neurology issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Dubey is an associate professor in the departments of neurology and laboratory medicine and pathology at the Mayo Clinic in Rochester, Minnesota. Additional Resources Read the article: Autoimmune Neuromuscular Disorders Associated With Neural Antibodies Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Guest: @Div_Dubey Transcript Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME.   Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. Today, I'm interviewing Dr Divyanshu Dubey about his article on autoimmune neuromuscular disorders associated with neural autoantibodies, which is part of the August 2024 Continuum issue on autoimmune neurology. Welcome to the podcast. How are you?   Dr Dubey: Hi, Dr Monteith. Thank you for inviting me to be a part of this podcast. I'm doing well.   Dr Monteith: Well, why don't you introduce yourself to the audience? And, call me Tesha.   Dr Dubey: I'm Divyanshu Dubey (please, call me Div). I'm one of the autoimmune neurology consultants here at Mayo Clinic Rochester. I'm an Associate Professor of neurology, as well as lab medicine and pathology. My responsibilities here are split - partly seeing patients (primarily patients with autoimmune disorders, including neuromuscular disorders), and then 50% of my time (or, actually, more than 50%), I spend in the lab, either doing research on these autoimmune disorders or reporting antibodies in a clinical setting for various antibody panels which Mayo's neuroimmunology lab offers.   Dr Monteith: That's a nice overlap of subspecialty area. How did you get into this work?   Dr Dubey: I think a lot of it was, sort of, by chance. Meeting the right people at the right time was the main, sort of, motivation for me. Initially, I trained in India for my medical school and didn't really got much exposed to autoimmune neurology in India. I think our primary concern in my training was sort of treating TB meningitis and cerebral malaria - that was my exposure to neurology, including stroke and some epilepsy cases. As a part of application for USMLEs and coming here to residency, I did some externships, and one of the externships was at Memorial Sloan Kettering Cancer Center, and that's when I worked a few weeks with Dr Posner and got introduced to the idea of paraneoplastic neurological syndrome working with him. And that sort of started - I wouldn't call it vicious cycle - but my interest in the area of autoimmune neurology and paraneoplastic neurological disorders, which subsequently was refined further through residency and fellowships.   Dr Monteith: That's interesting. I actually rotated through - I did a externship also at Sloan Kettering, and I had a clinic with Dr Posner. And I thought, at the time, he was such a rock star, and, like, I took a picture with him, and I think he thought it was insane. And I didn't go into autoimmune neurology. So, you know, interesting pathways, right?   Dr Dubey: Yes. And I think he's inspired many, many people, and sort of trained a lot of them as well.   Dr Monteith: So, why don't you tell us what you set out to do when writing this article?   Dr Dubey: So, I think, given my background and training in various subspecialties in neurology, I was, sort of, formally did fellowships in autoimmune neurology, as well as neuromuscular medicine. One of the areas in these areas that I focus on is in my clinical practice, as well as in my sort of lab work, is autoimmune muscular disorders - and that to, specifically, autoantibodies and their clinical utility for autoimmune muscular disorders. So, that's what I wanted to focus on in an article. When I was invited to write an article on autoimmune muscular conditions in general, I thought it was very difficult to pack it all in one chapter or one article, so I narrowed my focus (or tilted my focus) towards antibody-positive disorders and trying to understand how we as neurologists can firstly sort of identify these conditions (which may end up being antibody-positive) – and then, on the other hand, once we get these antibody results, how we can find the utility in them or find them useful in taking care of our patients. At the same time, I also wanted to kind of highlight that these antibodies are not perfect, they do have certain limitations – so, that's another thing I sort of highlighted in the article.   Dr Monteith: So, why don't we just start with a very broad question - what do you believe the role of autoantibodies is in the workup of neuropathies and then neuromuscular disorders? Obviously, when we think of myasthenia gravis, but there are some presentations that you may not necessarily think to first order autoantibody tests. So, what is the role, and where does it fit in the paradigm?   Dr Dubey: I think it's extremely crucial, and it's evolving as time goes on, and it's becoming more and more clinically relevant. Let's say three, four decades ago, the number of biomarkers which were available were very limited and only a handful - and there has been a significant increase in these biomarkers with growing utilization of newer techniques for discovery of antibodies, and more and more people jumping into this field trying to not only discover, but try and understand and validate these biomarkers (what they truly, clinically mean). These antibodies, like you pointed out, ones for myasthenia (such as acetylcholine receptor-binding antibodies, or MuSK antibodies), they can be extremely helpful in clinical diagnosis of these patients. We all know the importance of EMG in managing our patients with neuromuscular disorders. But, oftentimes, EMG nerve conduction studies are often not available at every center. In those scenarios, if you have antibodies with very high clinical specificity, and you're seeing a patient on examination whom you're seeing ptosis (fatigable ptosis), double vision, you're suspecting myasthenia, you send antibodies, and they come back positive. It brings you closer to the answer that may, in turn, require you to refer to a patient to a place where you can get high-quality EMGs or high-quality care. In addition to getting to the diagnosis, it also, sometimes, leads you in directions to search for what is the trigger. A good example is all these paraneoplastic neurological syndromes (which we started our conversation with), where once you find a biomarker (such as anti-Hu antibodies or CRMP5 antibodies) in a patient with paraneoplastic neuropathies, it can direct the search for cancer. These are the patients where, specifically, these two antibodies, small-cell lung cancer is an important cancer to rule out - they require CT scans, and if those are negative, consider doing PET scan – so, we can remove the inciting factor in these cases. And then, lastly, it can guide treatment. Depending upon subtypes of antibodies or particular antibodies, it can give us some idea what is going to be the most effective treatment for these patients.   Dr Monteith: I think paraneoplastic syndromes are a very good example of how autoantibodies can help guide treatment. But, what other examples can you provide for us?   Dr Dubey: Yeah, so I think one of the relatively recent antibody tests which our lab started offering is biomarkers of autoimmune neuropathies - these are neurofascin and contactin, and those are great examples which can target or guide your treatment. I personally, in the past, have had many CIDP patients before we were offering these testings, where we used to kind of start these patients on IVIG. They had the typical electrodiagnostic features, which would qualify them for CIDP. They did not show any response. In many of these cases, we tried to do sort of clinical testing or sort of research-based testing for neurofascin and contactin back in the day, but we didn't have this resource where we can sort of send the blood, hopefully, and within a week, get an answer, whether these patients have autoimmune neuropathy or not. Having this resource now, in some of these cases, even before starting them on IVIG, knowing that test result can guide treatments, such as considering plasma exchange up front as a first-line therapy, followed by rituximab or B-cell depleting therapies, which have been shown to be extremely beneficial in these conditions. And it is not just limited to neurofascin or contactin (which are predominantly IgG4-mediated condition), but the same concept applies to other IgG4-mediated diseases, such as MuSK myasthenia, where having an antibody result can guide your treatment towards B-cell depleting therapies instead of sort of trying the typical regimen that you try for other myasthenia gravis patients.   Dr Monteith: And you mentioned where I was reading that, sometimes, nerve conduction studies and EMG can be useful to then narrow the autoantibody profiles. Oftentimes, in the inpatient service, we order the autoantibodies much faster, because it's sometimes harder to access EMG nerve conduction studies - but talk about that narrowing process.   Dr Dubey: Yeah. And it goes back to the point you just made where we end up sending, sort of, sometimes (and I'm guilty of this as well), where we just send antibodies incessantly, even knowing that this particular patient is not necessarily likely to be an autoimmune neurological disorder, and that can be a challenge, even if the false-positive rate for a particular test is, let's say 1% - if you send enough panels, you will get that false-positive result for a particular patient. And that can have significant effects on the patient - not only unnecessary testing or imaging (depending on what type of antibody it is), but also exposure to various immunotherapies or immunosuppressive therapies. It's important to recognize red flags – and that's one of the things I've focused on in this article, is talking about clinical, as well as electrodiagnostic, factors, which make us think that this might be an autoimmune condition, and then, subsequently, we should consider autoantibody testing. Otherwise, we can be in a situation - that 1% situation - where we may be sort of dealing with a false-positive result, rather than a true-positive result. In terms of EMGs, I think I find them extremely useful, specifically for neuropathies, distinguishing between demyelinating versus exonal, and then catering our antibody-ordering practices toward specific groups of antibodies which are associated with demyelinating neuropathies (if that's what the electrophysiology showed) versus if it's an exonal pathology (considering a different subset of antibodies) - and that's going to be extremely important.   Dr Monteith: You're already getting to my next question, which is what are some of the limitations of autoantibody testing? You mentioned the false-positivity rate - what other limitations are there?   Dr Dubey: So, I think the limitations are both for seropositive, as well as seronegative, patients. As a neurologist, when we see patients and send panels, we can be in a challenging situation in both of those scenarios. Firstly, thinking about seropositives - despite the growing literature about neurology and antibodies, we have to be aware, at least to some extent, about what methodologies are being utilized for these antibody tests. And what I mean by that is knowing when you're sending a sample to a particular lab, the methodology that they're utilizing - is that the most sensitive, specific way to test for certain antibodies? We've learned about this through some of the literature published regarding MOG and aquaporin-4, which has demonstrated that these antibodies, which we suspect are cell surface antibodies, not only generate false-positive, but also false-negative results if they are tested by Western blots or ELISAs. Similar can be applied to some of the cell surface antibodies we are investigating on the autoimmune neuromuscular side (we have some sort of unpublished data regarding that for neurofascin-155). Secondly, it's also kind of critical when you're getting these reports to kind of have a look at what type of secondary antibodies are being utilized, an example being we talked about neurofascin-155, and I mentioned these are IgG4-predominant diseases, so testing for neurofascin IgG4 and knowing that particular patient is positive IgG4 rather than neurofascin pan-IgG. That's an important discrimination, and important information for you to know, because we have seen, at least in my clinical practice, that patients who are positive for neurofascin IgG4 follow the typical story of autoimmune neuropathies - the ones who are not (who are just neurofascin-155 IgG-positive), oftentimes can have wide-ranging phenotypes. The same applies to neurofascin-155 IgMs. And then (not for all antibodies, but for some antibodies), titers are important. A good example of that is a3 ganglionic receptor antibodies, which we utilize for when we're taking care of patients who have autoimmune dysautonomia - and in these cases, if the titers of the antibodies are below .2 nmol/L, usually, those don't have a high specificity for AAG diagnosis. So, I get referred a lot of patients with very low titers of a3 ganglionic receptor antibodies, where the clinical picture does not at all look like autoimmune autonomic ganglionopathy. So, that's another thing to potentially keep in mind. And then, on the seronegative front, it's important to recognize that we are still sort of seeing the tip of the iceberg as far as these antibodies or biomarkers are concerned, specifically for certain phenotypes, such as CIDP. If you look at the literature, depending upon what demographics we're looking at or sort of racial profiles we're looking at, the frequency of these autoimmune neuropathy biomarkers range from 5% to 20%, with much higher frequency in Asian patients - so, a good chunk of these diseases are still seronegative. In the scenario where you have a very high suspicion for an autoimmune neuromuscular disorder (specifically, we'll talk about neuropathies, because that's why we utilize tissue immunofluorescence staining on neural tissues), I recommend people to potentially touch base with that tertiary care lab or that referral lab to see if they have come across some research-based antibodies which are not clinically validated, which can give you some idea, some additional supportive idea, that what you're dealing with is an autoimmune neuromuscular disorder. So, we have to keep the limitations of some of these antibody panels and antibody tests in mind for both positive, as well as negative, results.   Dr Monteith: So, you've already given us a lot of good stuff, um, about titer seronegativity and false-positive rates. And, you know, also looking at the clinical picture when ordering these tests, utilizing EMG nerve conduction studies, give us a major key point that we can't not get when reading your article.   Dr Dubey: I think the major key point is we are neurologists first and serologists later. Most of these patients, we have to kind of evaluate them clinically and convince ourselves at least partly that this might be an autoimmune neuromuscular disorder before sending off these panels. Also, I find it useful to narrow down the phenotype, let's say, in a particular neuropathy or a muscle disease or a hyperexcitability syndrome. So, I have a core group of antigens, autoantigens, or autoantibodies, which I'm expecting and making myself aware of - things beyond that will raise my antenna - potentially, is this truly relevant? Could this be potentially false-positive? So, clinical characterization up front, phenotypic characterization upfront, and then utilizing those antibody results to support our clinical decision-making and therapeutic decision-making is what I've tried to express in this article.   Dr Monteith: And what is something that you wish you knew much earlier in your career?   Dr Dubey: It's a very challenging field, and it's a rapidly evolving field where we learn many things nearly every year, and, sometimes, we learn things that were previously said were incorrect, and we need to kind of work on them. A good example of that is initial reports of voltage-gated potassium-channel antibodies. So, back in the day when I was actually in my medical school and (subsequently) in my residency, voltage-gated potassium-channel antibodies were closely associated with autoimmune neuromyotonia, or autoimmune peripheral hyperexcitability syndromes. Now, over time, we've recognized that only the patients who are positive for LGI1 or CASPR2 are the ones who truly have autoimmune neuromuscular disorders or even CNS disorders. The voltage-gated potassium-channel antibody by itself, without LGI1 or CASPR2, truly doesn't have a very high specificity for neurological autoimmunity. So, that's one example of how even things which were published were considered critical thinking or critical knowledge in our field of autoimmune neuromuscular disorders has evolved and has sort of changed over time. And, again, the new antibodies are another area where nearly every year, something new pops up - not everything truly stands a test of time, but this keeps us on our toes.   Dr Monteith: And what's something that a patient taught you?   Dr Dubey: I think one of the things with every patient interaction I recognize is being an autoimmune neurologist, we tend to focus a lot on firstly, diagnosis, and secondly, immunotherapy - but what I've realized is symptomatic and functional care beyond immunotherapy in these patients who have autoimmune neurological disorders is as important, if not more important. That includes care of patients, involving our colleagues from physical medicine and rehab in terms of exercise regimen for these patients as we do immunotherapies, potentially getting a plan for management of associated pain, and many other factors and many other symptoms that these patients have to deal with secondary to these autoimmune neurological conditions.   Dr Monteith: I think that's really well said, because we get excited about getting the diagnosis and then getting the treatment, but that long-term trajectory and quality of life is really what patients are seeking.   Dr Dubey: Yeah, and as you pointed out, most of the time, especially when we are in inpatient service, or even when we're seeing the patients upfront outpatient, we are seeing them, sometimes, in their acute phase or at their disease not there. What we also have to realize is, what are the implications of these autoimmune neurological conditions in the long term or five years down the line? And that's one of the questions patients often ask me and how this can impact them even when the active immune phase has subsided - and that's something we are actively trying to learn about.   Dr Monteith: So, tell me something you're really excited about in your field.   Dr Dubey: I think, firstly (which is pretty much the topic of my entire article), is novel antibodies and new biomarker discoveries. That's very exciting - we are actively, ourselves, involved in the space. The second thing is better mechanistic understanding of how these antibodies cause diseases, so we can not only understand diseases, we can also try and understand how to target and treat these diseases - this is being actively done for various disorders. One of the disorders which continue to remain a challenge are T-cell mediated diseases, where these antibodies are just red flags or biomarkers are not causing the disease, but it's potentially the T-cells possibly attacking the same antigen which are causing disease process, and those are often the more refractory and harder-to-treat conditions. I'm hoping that with some of the work done in other fields (such as rheumatology or endocrinology for type one diabetes), we're able to learn and apply the same in the field of autoimmune neurology and autoimmune neuromuscular medicine. And then, the final frontier is developing therapies which are antigen specific, where you have discovered that somebody has a particular antibody, and if that antibody is pathogenic, can I just deplete that antibody, not necessarily pan-depleting the immune system. And there is some translational data, there's some animal model data in that area, which I find very exciting, will be extremely helpful for many of my patients.   Dr Monteith: So, very personalized targeted therapies?   Dr Dubey: Correct. Without having all the side effects we all have to kind of take care of in our patients when we start them on, let's say, cyclophosphamide, or some of these really, really, significantly suppressive immunosuppressive medications.   Dr Monteith: Well, thank you so much. I learned a lot from reading your article to prepare for this interview, but also just from talking to you. And it's clear that you're very passionate about what you do and very knowledgeable as well, so, thank you so much.   Dr Dubey: Thank you so much. Thank you for inviting me to do this. And thank you for inviting me to contribute the article.   Dr Monteith: Today, I've been interviewing Dr Divyanshu Dubey, whose article on autoimmune neuromuscular disorders associated with neural autoantibodies appears in the most recent issue of Continuum on autoimmune neurology. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining us today.   Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information, important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at Continpub.com/AudioCME. Thank you for listening to Continuum Audio.

In the fourth episode of the 4 Es series, Julia is joined by Sunita, whose experience spans across continents in the field of renewable energy. Leading in different contexts has taught her how to combine seemingly opposite ideas and the one she holds closest is her ability to balance humility with assertiveness. Every new context offers and opportunity to unlearn and re-learn, she say, for the pace, the language and the mode of working may change. This is where humility is necessary. At the same time, it is important to be confident and assertive when it comes to your subject matter. Sunita offers a range of tools and phrases she keeps handy when working with the various kinds of energy one encounters when leading a team. How can you learn to be empathetic but also have clear boundaries? How do you learn to run a successful and healthy team in vastly different context?About the Guest: Sunita Dubey is the Country Representative for the GEAPP in Vietnam and leads battery energy storage system work in the region. She has 25+ years of combined experience in the energy sector in South Asia, Southeast Asia, and Africa. She has double master's in environmental science and energy policy and is a Chevening fellow.

Hey CX Nation,In this week's episode of The CXChronicles Podcast #237 we were live at Customer Contact Week in the Caesar's Forum Entertainment Center in Las Vegas last month with Ashu Dubey, CEO at Gleen AI based in the San Francisco Bay Area, CA. Ashu and his team are building Gleen AI - The most accurate and capable generative AI platform for customer support and success! Generative AI has ushered in a new-era for customer support and they help businesses scale their customer support at a fraction of the cost using Gleen AIIn this episode, Ashu and Adrian chat through the Four CX Pillars: Team, Tools, Process & Feedback. Plus share some of the ideas that his team think through on a daily basis to build world class customer experiences.**Episode #237 Highlight Reel:**1. How Generative AI/ML is changing the customer landscape rapidly 2. Equipping your customer facing team with "agent-assist" solutions 3. What we can all learn about AI from Meta, Amazon, Google & others4. Educating customers & employees on where AI will lead us 5. Leveraging AI to expedite the growth of your business Click here to learn more about Ashu Dubey Click here to learn more about Gleen AIHuge thanks to Ashu for coming on The CXChronicles Podcast and featuring his work and efforts in pushing the customer experience & customer success space into the future.If you enjoy The CXChronicles Podcast, stop by your favorite podcast player hit the follow button and leave us a review today.For our Spotify friends, click here to make sure you are following CXC & please leave a 5 star review so we can find new listeners & members of our community.For our Apple friends, same deal -- click here to follow CXCP and leave us a review letting folks know why you love our customer focused content.You know what would be even better?Go tell one of your friends or teammates about CXC's content,  our strategic partners (Hubspot, Intercom, Zendesk, Forethought AI, Freshworks, TimeToReply & Ascendr) + they can learn more about our CX/CS/RevOps services & please invite them to join the CX Nation!Are you looking to learn more about the world of Customer Experience, Customer Success & Revenue Operations?Click here to grab a copy of my book "The Four CX Pillars To Grow Your Business Now" available on Amazon or the CXC website.For you non-readers, go check out the CXChronicles Youtube channel to see our customer & employee focused business content. Reach Out To CXC Today!Support the Show.Contact CXChronicles Today Tweet us @cxchronicles Check out our Instagram @cxchronicles Click here to checkout the CXC website Email us at info@cxchronicles.com Remember To Make Happiness A Habit!!

durée : 00:58:46 - "The Gentle Rain" ("Chuva Delicada") (Luiz Bonfa / Matt Dubey) (1965) - par : Laurent Valero - "Thème de musique de film, plus connu que l'œuvre cinématographique The Gentle Rain, le nom de ce thème composé pour le film américano-brésilien du même nom, sorti en 1965 sur les écrans par le guitariste virtuose, compositeur brésilien Luiz Bonfá qui n'en était pas à ses débuts..." Laurent Valero

Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 assays facilitate care for central nervous system disorders triggered by cancer. Early diagnosis and treatment are important for managing disabling neurological symptoms and malignancy.(00:32) Could you tell us a bit about your background and your role at Mayo Clinic? (01:26) How do the tests that are coming live relate to the larger disease state of neurological disorders? (02:44) Can you share a little bit about the methodology we're using for these particular biomarkers?  (05:15) How was PDE10A discovered? (06:48) Anything you would add? (07:50) Remind us which phenotype-specific assays these biomarkers are being added to, and how physicians should determine whether this testing is appropriate? (09:55) What does early detection of these biomarkers mean for the patient's prognosis, diagnosis, treatment, etc.? (12:33) What are you most excited about with the launch of these tests?

Edited highlights of our full length conversation. Are you seizing what is starting? This episode is the third in a series of conversations I'm having in partnership with the Cannes Lions Festival of Creativity. For the weeks leading up to Cannes, we're focusing our study of leadership through a single lens. The impact of Artificial Intelligence on the Creative Industries. Are we moving fast enough? Are we going far enough? Is this an opportunity to fundamentally redesign the creative industries, or should we adjust and iterate, slowly and carefully? Do we follow the puck or skate to where it's going? There are opportunities and risks around every corner. Asmita Dubey is the Chief Digital and Marketing Officer of L'Oréal. Her company is the fourth largest advertiser in the world. They are a 115-year old business that owns 37 brands. It's easy to see the world presumptively. To presume that big companies always move more cautiously, that they are slower to see, to adopt, and to adapt to disruptions in the eco system around them. But if your company believes, as Asmita frames it, in seizing what is starting, if you operate from a foot forward perspective, if you are relentlessly curious and consistently committed to the belief that creativity and innovation are all that separates you from your competitors, then the size of your company does not matter. Big or small. Old or new. You can seize what is starting, and define the future on your terms. At the end of the series, I'll offer some thoughts on what we've heard and learned, and where we might go from here. In the meantime, thanks for joining us.

Edited highlights of our full length conversation. Are you seizing what is starting? This episode is the third in a series of conversations I'm having in partnership with the Cannes Lions Festival of Creativity. For the weeks leading up to Cannes, we're focusing our study of leadership through a single lens. The impact of Artificial Intelligence on the Creative Industries. Are we moving fast enough? Are we going far enough? Is this an opportunity to fundamentally redesign the creative industries, or should we adjust and iterate, slowly and carefully? Do we follow the puck or skate to where it's going? There are opportunities and risks around every corner. Asmita Dubey is the Chief Digital and Marketing Officer of L'Oréal. Her company is the fourth largest advertiser in the world. They are a 115-year old business that owns 37 brands. It's easy to see the world presumptively. To presume that big companies always move more cautiously, that they are slower to see, to adopt, and to adapt to disruptions in the eco system around them. But if your company believes, as Asmita frames it, in seizing what is starting, if you operate from a foot forward perspective, if you are relentlessly curious and consistently committed to the belief that creativity and innovation are all that separates you from your competitors, then the size of your company does not matter. Big or small. Old or new. You can seize what is starting, and define the future on your terms. At the end of the series, I'll offer some thoughts on what we've heard and learned, and where we might go from here. In the meantime, thanks for joining us.

Are you seizing what is starting? This episode is the third in a series of conversations I'm having in partnership with the Cannes Lions Festival of Creativity. For the weeks leading up to Cannes, we're focusing our study of leadership through a single lens. The impact of Artificial Intelligence on the Creative Industries. Are we moving fast enough? Are we going far enough? Is this an opportunity to fundamentally redesign the creative industries, or should we adjust and iterate, slowly and carefully? Do we follow the puck or skate to where it's going? There are opportunities and risks around every corner. Asmita Dubey is the Chief Digital and Marketing Officer of L'Oréal. Her company is the fourth largest advertiser in the world. They are a 115-year old business that owns 37 brands. It's easy to see the world presumptively. To presume that big companies always move more cautiously, that they are slower to see, to adopt, and to adapt to disruptions in the eco system around them. But if your company believes, as Asmita frames it, in seizing what is starting, if you operate from a foot forward perspective, if you are relentlessly curious and consistently committed to the belief that creativity and innovation are all that separates you from your competitors, then the size of your company does not matter. Big or small. Old or new. You can seize what is starting, and define the future on your terms. At the end of the series, I'll offer some thoughts on what we've heard and learned, and where we might go from here. In the meantime, thanks for joining us.

In this episode of InTechnology, Camille gets into parallel computing with Pradeep Dubey, Intel Senior Fellow at Intel Labs. They talk about how parallel computing works, why it's becoming more necessary, how it uses AI and machine learning to process large amounts of data, the challenges of designing systems and architecture for parallel computing, how machines can help humans make better decisions, and much more. The views and opinions expressed are those of the guests and author and do not necessarily reflect the official policy or position of Intel Corporation.

Ashu Dubey is the CEO and Co-Founder of Gleen, a leading generative AI-based customer service solution. As a serial AI entrepreneur, Ashu previously was CTO and Co-Founder of 12 Labs, an early pioneer in AI-powered personalized health recommendations. Ashu led top of the funnel user growth at LinkedIn, where he significantly accelerated user growth and was instrumental in launching innovative products such as LinkedIn Events. Ashu has an MBA from UCLA, attended IIT Dhanbad, and consistently merges technology and innovation to shape industry landscapes.In This Conversation We Discuss: [00:40] Intro[01:47] Bridging Discord and Ecommerce gaps[03:08] The importance of reliable AI in business[04:25] Balancing AI risks and benefits[04:49] Limitations of ChatGPT integration[06:09] Aligning AI abilities with customer expectations[07:05] Improving your AI tool through feedbacks[07:35] Safeguarding customer information[08:35] Editing and customizing AI responses[09:43] Incorporating AI into help desks[10:26] Testing AI exposure levels on customers [11:03] Seamless Setup with Gleen AI[12:10] Gleen's quick turnaround for integration requests[12:27] Unified suite of AI services with Gleen AI[14:17] Gleen's special offer for Honest Ecommerce listeners[15:01] The omnichannel capability of Gleen[15:50] Find Ashu on LinkedIn and Twitter/XResources:Subscribe to Honest Ecommerce on YoutubeGenerative AI platform for customer success https://gleen.ai/Follow Ashu Dubey https://www.linkedin.com/in/ashudubeyIf you're enjoying the show, we'd love it if you left Honest Ecommerce a review on Apple Podcasts. It makes a huge impact on the success of the podcast, and we love reading every one of your reviews!

Welcome back to eCommerce Fastlane, the go-to podcast guiding you through the twists and turns of digital retail. I'm your host, Steve Hutt, and today we've got a thrilling episode lined up for you!Joining us in the fast lane is Ashu Dubey, CEO and co-founder of Glean AI, an incredible generative AI platform that's making waves in the ecommerce world. Ashu is here to reveal the inner workings of a solution that's not only helping brands maximize profitability but also ensuring efficiency through a unique AI lens.Today, we'll delve into the founding story behind Glean AI and the passion that drives its cutting-edge technology. As we explore the platform that boasts non-hallucinatory responses and supports over 90 languages, we'll discover how it seamlessly integrates with Shopify and elevates the capabilities of non-tech professionals in marketing, customer support, and sales.Did I mention an exclusive offer? That's right, Ashu's generously offering our listeners $2.50 in conversation credits on their paid plans, so be sure to listen out for the special link to sign up.And for all you hot sleepers out there, don't miss Ashu's top pick, the Puffy Cooling Cloud Foam Mattress – a game-changer recommended just for you.Ready to dive into the truth about AI in ecommerce? Let's debunk some misconceptions, learn about keeping brand tones in AI responses, and find out why integration, not replacement, is the key to leveraging AI tools. Buckle up; it's going to be an enlightening ride on eCommerce Fastlane!Reach out to us! We welcome questions and comments about this episode. Connect with us here or through our socials — your feedback is always welcome.TwitterLinkedInFacebookFor more ecommerce, marketing, and growth strategies, check out the eCommerce Fastlane Insights Blog.TOPICS INCLUDE: Advertising, Affiliate Marketing, Amazon, Attribution, Automation, B2B, Brand, Customer Retention, Customer Support, Data + Analytics, Data Trust + Security, Dropshipping, Ecommerce SEO, Email Marketing, Entrepreneurship, Founder Stories, Influencer Marketing, Legal, Logistics, Shipping, Loyalty, Rewards, Retention Marketing, Marketing, Sales, Conversion, Money From Home, Operations, Payments, Finance, Tax, People, Personalization, Post Purchase Experience, Print On Demand, Product Development, Retail, Shopify POS, Reviews, Search, SMS Marketing, Social Commerce, Social Media, Live Shopping, Startup Ideas, Store Design, Mobile Apps, Sustainability, TikTok, Trends, Ultimate Guides, Web3, best Shopify apps, and more. Hosted on Acast. See acast.com/privacy for more information.

Watch the Full Episode for FREE: Gaurav Dubey - Decentralisation Is Our Biggest Weapon Against All Paradigms of Control - London Real

Watch the Full Episode for FREE: Gaurav Dubey - Decentralisation Is Our Biggest Weapon Against All Paradigms of Control - London Real

Watch this episode on YouTube- https://bijay.co/167  In this conversation: What Vivek Atray, an Ex-IAS officer learned about difficult conversations? How to Say NO to your superiors and colleagues? What did Vivek learn about his spiritual pursuit? How to pick your spiritual journey? Vivek Atray is Ex-IAS officer, renowned speaker, author, columnist, and cricket enthusiast. He has addressed diverse audiences, including the Indian Army and corporate giants. Atray has penned the book "FINDING SUCCESS WITHIN" and novels like "Move on Bunny!" and "Dubey ji Bounces Back." He writes a column for Hindustan Times and has played cricket at the national level. Send me a voice message: https://theinspiringtalk.com/speak   Connect with Vivek Atray     Website Instagram    Follow the Inspiring Talk on Facebook http://theinspiringtalk.com/facebook   Twitter http://theinspiringtalk.com/twitter Instagram http://theinspiringtalk.com/instagram

In this episode, we sat down with Vineet Dubey, an environmental litigator, to peel back the layers of environmental law. Vineet shares several eye-opening examples of how consumer products contain toxic compounds including lead in baby food, PFAS (forever chemicals) leeching from paper products, and microplastics in our water. Tune in to understand how you can become a conscientious consumer and easily avoid exposure to cancer-causing toxins. Watch the  Vice Documentary HERE.Find Vineet's work HERE. Find Custodio & Dubey on Instagram HERE. Find Custodio & Dubey on Tik Tok HERE.  Find Homegrown on Instagram HERE. Find Liz Haselmayer on Instagram HERE. Find Joey Haselmayer on Instagram HERE.Shop real food meal plans and children's curriculum HERE.Join our exclusive community HERE.Find us on YouTube HERE.Shop natural home goods on Haselmayer Goods HERE.